跳转至内容
Merck
CN
所有图片(2)

文件

MABN11

Sigma-Aldrich

抗-淀粉样蛋白β40抗体,克隆G2-10

clone G2-10, from mouse

登录查看公司和协议定价

别名:
Alzheimer disease, Alzheimer disease amyloid protein, Cerebral vascular amyloid peptide, Protease nexin-II, amyloid beta (A4) precursor protein, amyloid beta A4 protein, amyloid beta precursor protein, beta-amyloid peptide, human mRNA for amyloid A4 prec
UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物来源

mouse

质量水平

抗体形式

purified antibody

克隆

G2-10, monoclonal

种属反应性

human, mouse

技术

ELISA: suitable
immunohistochemistry: suitable
western blot: suitable

同位素/亚型

IgG2bκ

NCBI登记号

UniProt登记号

运输

wet ice

靶向翻译后修饰

unmodified

基因信息

human ... APP(351)

一般描述

与阿尔茨′海默病(AD)相关的脑和血管斑块主要由淀粉样蛋白β肽(Aβ)组成。Aβ衍生自淀粉样蛋白前体蛋白(APP)的切割,长度在39至43个氨基酸之间变化。Aβ [1-40]、Aβ [1-42]和Aβ [1-43]肽分别来自残基40、42和43后APP的裂解。切割是在最后一个APP处理步骤中通过γ-分泌酶进行的。Aβ[1-40]、[1-42]和[1-43]肽是AD中发生的斑块和缠结的主要成分。Aβ抗体和肽已被开发为阐明AD生物学的工具。

特异性

该抗体可识别C末端的淀粉样蛋白β40。

免疫原

C末端的人淀粉样蛋白β40的线性肽。
表位:C末端

应用

使用经验证可用于WB、IH、ELISA的抗淀粉样蛋白β40抗体(克隆G2-10)检测淀粉样蛋白β40。
免疫组织化学分析: 一个先前批次以1:300稀释度在阿尔茨’海默病的海马组织中检测到淀粉样蛋白β40。
研究子类别
神经退行性疾病
研究类别
神经科学

质量

通过蛋白质印迹法在APP转基因CRND8小鼠脑裂解物中进行评估。

蛋白质印迹分析:1 µg/ml的该抗体在10 µg APP转基因CRND8小鼠脑裂解物上检测到淀粉样蛋白β40。

目标描述

约4 kDa

外形

形式:纯化
纯化的小鼠单克隆IgG2bκ,溶于含0.1 M Tris-甘氨酸(pH 7.4,150 mM NaCl)、0.05%叠氮化钠和1% BSA的缓冲液中。
纯化蛋白G

储存及稳定性

自接收之日起,在2-8°C下可稳定保存1年。

分析说明

对照
APP转基因CRND8小鼠脑裂解物

其他说明

浓度:关于批次特定浓度请参见检验报告。

免责声明

除非我们的目录或产品随附的其他公司文件中另有说明,否则我们的产品预期仅用于研究用途,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或对人类或动物的任何类型的消费或应用。

WGK

WGK 1


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Vanessa Kurth et al.
The Journal of biological chemistry, 299(8), 104997-104997 (2023-07-03)
Presenilin-1 (PSEN1) is the catalytic subunit of the intramembrane protease γ-secretase and undergoes endoproteolysis during its maturation. Heterozygous mutations in the PSEN1 gene cause early-onset familial Alzheimer's disease (eFAD) and increase the proportion of longer aggregation-prone amyloid-β peptides (Aβ42 and/or
Ditte Z Christensen et al.
Frontiers in aging neuroscience, 6, 139-139 (2014-07-16)
Abnormalities and impairments in axonal transport are suggested to strongly contribute to the pathological alterations underlying AD. The exact mechanisms leading to axonopathy are currently unclear, but it was recently suggested that APP expression itself triggers axonal degeneration. We used
Ge Li et al.
International journal of molecular medicine, 42(4), 1935-1944 (2018-08-08)
Aging is associated with impairment of the paravascular pathway caused by the activation of astrocytes and depolarization of protein aquaporin‑4 (AQP4) water channels, resulting in the accumulation of protein waste, including amyloid β (Aβ), in the brain parenchyma. The secreted
Kevin Kleffman et al.
Cancer discovery, 12(5), 1314-1335 (2022-03-10)
Brain metastasis is a significant cause of morbidity and mortality in multiple cancer types and represents an unmet clinical need. The mechanisms that mediate metastatic cancer growth in the brain parenchyma are largely unknown. Melanoma, which has the highest rate
Jin Cui et al.
Cell discovery, 1, 15021-15021 (2015-01-01)
Despite decades of intense global effort, no disease-modifying drugs for Alzheimer's disease have emerged. Molecules targeting catalytic activities of γ-secretase or β-site APP-cleaving enzyme 1 (BACE1) have been beset by undesired side effects. We hypothesized that blocking the interaction between

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门